Generate Biomedicines, Inc. (GENB) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$12.20

From 52W high−38.37%

Volume675223.00

Market cap$1.61B

P/E (TTM)—

P/S (TTM)50.5x

Div yield—

Key dataOct 19, 2026

Open

$12.20

From 52W high

−38.37%

Volume

675223.00

Market cap

$1.61B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−5.8x

P/E (TTM)

—

RSI (14)

38.3

MomentumView details →

1D Return

+3.89%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−5.8x

EV/Sales

38.2x

P/S (TTM)

50.5x

P/B (TTM)

3.5x

ProfitabilityView details →

Gross Margin

100.00%

Net Margin

−636.99%

EBITDA Margin

−653.71%

ROE (TTM)

−44.55%

ROA (TTM)

−36.17%

Asset Turnover

0.05x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+55.89%

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+3.89%

YTD Return

—

1Y Return

—

RSI (14)

38.3

vs 50D SMA

−18.12%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

0.14x

Current Ratio

8.30x

Quick Ratio

8.30x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.52

EPS Surprise

−2.30%

Beats (12Q)

0/12

Next Q EPS Est

−$0.58

Avg Surprise (4Q)

−70.04%

Rev Surprise

19.13%

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Next earningsNov 5, 2026 →

Latest newsMore news →

Generate Biomedicines, Inc. and Zealand Pharma A/S entered a collaboration and license agreement to develop AI-engineered protein therapeutics for metabolic diseases.6d ago

Roswell Park Comprehensive Cancer Center and Generate Biomedicines launched an exclusive clinical trial of the AI-engineered CAR T therapy GB-5267 for ovarian cancer, with the first patient treated.19d ago

Similar companies

Sixth Street Specialty Lending, Inc.TSLX JOHCM Emerging Markets Opps InvestorJOEAX NexPoint Merger Arbitrage ZHMEZX JPMorgan SmartRetirement Blend Inc R5JIBBX American Century One Choice Mod InvAOMIX State Street Global All Cap Equity ex-US Index PortfolioSSGVX Find similar companies →

Latest newsMore news →

Generate Biomedicines, Inc. and Zealand Pharma A/S entered a collaboration and license agreement to develop AI-engineered protein therapeutics for metabolic diseases.6d ago Roswell Park Comprehensive Cancer Center and Generate Biomedicines launched an exclusive clinical trial of the AI-engineered CAR T therapy GB-5267 for ovarian cancer, with the first patient treated.19d ago